Yan Liu

Prof. Yan Liu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

2 December 2023 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
FGFeilin Ge
Feilin Ge
YYYan Yang
Yan Yang
ZBZhaofang Bai
Zhaofang Bai
LSLanlan Si
Lanlan Si
XWXuemei Wang
Xuemei Wang
ZRZhigang Ren
Zhigang Ren
Chronic hepatitis B (CHB) remains a major world's most serious public health issues. Despite the remarkable effect of nucleos(t)ide analogues (NAs) in inhibiting hepatitis B virus (HBV) deoxyribonucleic acid (DNA) as the first-line drug, there are several limitations still, such as poor antigen inhibition, drug resistance, low-level viremia, restricting patients' functional cure. Due to the constraints of NAs, traditional medicines, such as traditional Chinese medicine (TCM), have become more prevalently used and researched in the clinical treatment of CHB as complementary alternative therapies. As a consequence, the review focuses on the background based on HBV’s life cycle as well as the NAs’ limitations, progress based on direct and indirect pathway of targeting HBV of TCM, and challenges of TCM. We found TCMs play an increasingly important role in anti-HBV. In a direct antiviral way, they regulate HBV infection, replication, assembly, and other aspects of the HBV life cycle. As for indirect way, TCMs can exert anti-HBV effects through targeting the host, including immune regulation, apoptosis, autophagy, oxidative stress, etc. Especially, TCMs have the advantages of strong antigenic inhibition compared to NAs. Specifically, we can combine the benefits of TCMs in strong HBV antigen inhibition with the benefits of NAs in targeted antiviral effects, in order to find a suitable combination of "TCM + NAs" to contribute to Chinese knowledge of the realisation of the “global elimination of HBV by 2030” goal of the World Health Organization.

1 June 2018 in Antiviral Research
Verified
Journal Article
Closed access
LZLi Zhao
Li Zhao
XLXiaodong Li
Xiaodong Li
YCYongqian Cheng
Yongqian Cheng
RCRongjuan Chen
Rongjuan Chen
JSJinman Shao
Jinman Shao
DXDongping Xu
Dongping Xu

14 July 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
HLHao Liao
Hao Liao
LLLe Li
Le Li
WZWei V. Zheng
Wei V. Zheng
JZJun Zou
Jun Zou
GYGuangxin Yu
Guangxin Yu
JCJunhui Chen
Junhui Chen
Background and aims. To investigate the clinical implications of serum HBV RNA, serum hepatitis B core-related antigen (HBcrAg), and quantitative anti-HBc in treatment-naïve patients with chronic HBV infection. Methods. A total of 111 patients in total from different disease phases were recruited, including 21 in immune-tolerant (IT) phase, 49 in immune-clearance (IC) phases, 29 in immune-control or low replicative (LR) phase, and 12 in reactivation phases. Serum HBV RNA, anti-HBc, HBcrAg, and intrahepatic covalently closed circular DNA (cccDNA) were quantified and each of these indicator’s correlation with liver inflammation was analyzed. Results. HBeAg-positive individuals had significant higher serum levels of HBV RNA and HBcrAg than those who were HBeAg negative, similar to that of serum HBV DNA. Comparatively, HBV RNA ( =0.79, ) and HBcrAg ( =0.78, ) had almost same higher overall correlation with the cccDNA, as that of HBV DNA ( =0.81, ). Serum anti-HBc level ( = -0.52, ) is negatively correlated with cccDNA level at IT phase rather than the other three phases. When set the cutoff value at 4.00 log10 IU/mL, serum anti-HBc showed potential to indicate liver inflammation, with AUC as 0.79 and the specificities as 78.85% for HBeAg positive, and with AUC as 0.72 and the specificities as 62.16% for HBeAg-negative patients, respectively. Conclusions. In treatment-naïve patients, levels of serological markers HBV RNA and HBcrAg could mirror intrahepatic cccDNA level, but were not superior to HBV DNA level. Serum anti-HBc level had certain potential to be used as a predicting marker for liver inflammation.

7 April 2024 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FGFei-Lin Ge
Fei-Lin Ge
YYYan Yang
Yan Yang
LSLan-Lan Si
Lan-Lan Si
YLYuan-Hua Li
Yuan-Hua Li
MCMeng-Zhen Cao
Meng-Zhen Cao
YLYan Liu
Yan Liu
Inhibition of hepatitis B virus via selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet

3 April 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
YGYi‐Fan Guo
Yi‐Fan Guo
XNXiao‐Xia Niu
Xiao‐Xia Niu
LLLe Li
Le Li
YCYan Chen
Yan Chen
YLYan Liu
Yan Liu
DJDong Ji
Dong Ji